Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favorable effect on patients' health-related quality of life and pain. Only a few studies have investigated patient-reported outcomes (PROs) in AA treatment for mCRPC. The aim of this study was to investigate patients' satisfaction in men affected by mCRPC treated with AA.

Cindolo, L., Natoli, C., De Nunzio, C., De Tursi, M., Valeriani, M., Giacinti, S., et al. (2017). Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction. CLINICAL GENITOURINARY CANCER, 15(5), 520-525 [10.1016/j.clgc.2017.04.003].

Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction

Bove P.;Laudisi A.;
2017-01-01

Abstract

Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favorable effect on patients' health-related quality of life and pain. Only a few studies have investigated patient-reported outcomes (PROs) in AA treatment for mCRPC. The aim of this study was to investigate patients' satisfaction in men affected by mCRPC treated with AA.
2017
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/24 - UROLOGIA
English
Abiraterone acetate; Androgen deprivation therapy; Castration-resistant prostate cancer; Metastatic prostate cancer; Patient reported outcomes; Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Male; Patient Satisfaction; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retrospective Studies; Treatment Outcome
Cindolo, L., Natoli, C., De Nunzio, C., De Tursi, M., Valeriani, M., Giacinti, S., et al. (2017). Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction. CLINICAL GENITOURINARY CANCER, 15(5), 520-525 [10.1016/j.clgc.2017.04.003].
Cindolo, L; Natoli, C; De Nunzio, C; De Tursi, M; Valeriani, M; Giacinti, S; Micali, S; Rizzo, M; Bianchi, G; Martorana, E; Scarcia, M; Ludovico, Gm; Bove, P; Laudisi, A; Selvaggio, O; Carrieri, G; Bada, M; Castellan, P; Topazio, L; Boccasile, S; Ditonno, P; Chiodini, P; Schips, L
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/236707
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact